Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aeterna Zentaris Inc | AEZS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.96 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 1.3601 - 3.38 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 1.96 | USD |
Aeterna Zentaris Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
9.52M | 4.86M | - | 4.5M | -16.55M | -3.41 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aeterna Zentaris News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AEZS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.965 | 2.02 | 1.95 | 1.96 | 9,020 | -0.005 | -0.25% |
1 Month | 2.12 | 2.26 | 1.95 | 2.01 | 11,603 | -0.16 | -7.55% |
3 Months | 1.80 | 2.39 | 1.68 | 1.99 | 16,536 | 0.16 | 8.89% |
6 Months | 1.51 | 2.51 | 1.3601 | 1.98 | 15,131 | 0.45 | 29.80% |
1 Year | 3.20 | 3.38 | 1.3601 | 2.27 | 12,569 | -1.24 | -38.75% |
3 Years | 1.03 | 5.90 | 0.1645 | 0.6941188 | 618,366 | 0.93 | 90.29% |
5 Years | 3.91 | 5.90 | 0.1645 | 1.14 | 1,848,681 | -1.95 | -49.87% |
Aeterna Zentaris Description
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland. |